Get to know our clinical trials
Clinical trial to evaluate the safety, tolerability and pharmacokinetics of Seltorexant as adjunctive therapy to antidepressant treatment in adolescents with major depressive disorder who show an inadequate response to SSRI psychotherapy
THE OBJECTIVE OF THIS STUDY IS TO DETERMINE WHETHER SELTOREXANT (JNJ-42847922) AS AN ADJUNCTIVE TREATMENT TO THEIR CURRENT ANTIDEPRESSANT IS SAFE FOR THE TREATMENT OF PATIENTS WITH DEPRESSION (ALSO CALLED MAJOR DEPRESSIVE DISORDER [MDD]).
Madrid headquarters
Status
In recruitment
headquarters
Madrid
Early phase
Technical Summary
- SHORT-TERM EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SELTOREXANT AS ADJUNCTIVE THERAPY TO ANTIDEPRESSANT TREATMENT IN ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER WHO SHOW AN INADEQUATE RESPONSE TO SEROTONIN REUPTAKE INHIBITORS PLUS PSYCHOTHERAPY
- Code EudraCT: 2021-000567-77
- Protocol number: 42847922MDD1016
- Promoter: Janssen Research & Development
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.